59 results
8-K
EX-99.3
IVVD
Invivyd Inc
12 Sep 22
Adagio Therapeutics Announces Corporate Name Change to Invivyd
7:46am
candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; the anticipation of ongoing discussions … development and industry expertise brought to bear Company rapidly deploying best-in-class technology with an evolved strategy New name, renewed
8-K
EX-99.2
IVVD
Invivyd Inc
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
, strategy and expectations related to the launch and commercialization of PEMGARDA; our intention to pursue a rapid immunobridging pathway to potential … available, and the potential utility of generated data; potential alignment of our strategy and the evolving U.S. regulatory landscape; our expectation
8-K
EX-99.1
IVVD
Invivyd Inc
13 Oct 22
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery
4:16pm
positions and has eliminated several corporate and commercial positions, among others, to execute efficiently on the company’s corporate strategy, maximize … , we are shaping the organization to align with our corporate strategy and enable the company to fully capitalize on the potential of our integrated
8-K
EX-99.1
IVVD
Invivyd Inc
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us … and Prevention of Coronavirus Disease (COVID-19)
Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials
8-K
EX-99.1
IVVD
Invivyd Inc
12 Sep 22
Adagio Therapeutics Announces Corporate Name Change to Invivyd
7:46am
reflects the Company’s strategy for leveraging its integrated discovery platform to develop and commercialize antibodies that transcend the limits … website to reflect the company’s strategy moving forward. Visit www.invivyd.com to learn more.
About Invivyd
(Nasdaq: IVVD)
Invivyd, formerly Adagio
UPLOAD
8mjs0nya q1
16 Jun 21
Letter from SEC
12:00am
8-K
EX-99.2
jzs uwmnj
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
DRSLTR
tp2syvs5q
28 Jun 21
Correspondence regarding draft registration statement
12:00am
8-K
EX-99.1
7jgo htrlw9
3 Jan 24
Other Events
7:06am
8-K
EX-99.1
kplwbb8kgxs1g
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
EX-99.1
jnyuddawb
11 May 23
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
8-K
EX-99.1
9plud5mg2m 12l0ekt9
29 Jun 23
Other Events
7:08am
10-K/A
xevq3v7rf2sm7
29 Apr 22
Annual report (amended)
4:43pm
PRE 14A
ggdsa c8w
31 Mar 23
Preliminary proxy
4:36pm
DEF 14A
460tr822znw
10 Apr 23
Definitive proxy
4:07pm
8-K
EX-99.1
e17nteg
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
DEFC14C
ijtclr o32yxf870bc
2 Jun 22
Information statement in contested solicitation
4:24pm
PREC14C
puah7scgr
19 May 22
Preliminary information statement in contested solicitation
5:05pm